Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$13.67
-0.9%
$13.14
$10.45
$21.69
$4.89B0.621.02 million shs452,151 shs
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$34.80
-3.2%
$40.82
$26.56
$50.85
$1.04B0.83352,613 shs807,937 shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$82.35
+4.6%
$82.66
$41.50
$90.32
$4.18B-2.561.25 million shs1.07 million shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$114.50
-1.3%
$123.84
$55.00
$177.37
$3.96B2.091.40 million shs731,219 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-2.52%+0.65%-1.69%+22.56%-10.04%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-13.95%-14.30%-18.22%+5.73%+1.12%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-3.05%-8.97%-7.68%+2.53%+79.05%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-2.31%-2.45%-6.96%+4.08%-20.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
3.082 of 5 stars
3.11.00.00.03.31.72.5
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
1.7573 of 5 stars
3.40.00.00.01.62.50.6
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.5687 of 5 stars
4.51.00.04.63.32.50.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.6441 of 5 stars
2.42.00.00.03.22.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.20
Hold$15.5613.78% Upside
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
2.80
Moderate Buy$55.8060.34% Upside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.09
Buy$113.3037.58% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.78
Moderate Buy$123.007.42% Upside

Current Analyst Ratings Breakdown

Latest ESTA, BLCO, SLNO, and TMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$97.00 ➝ $106.00
8/7/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$105.00 ➝ $110.00
8/1/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $13.00
8/1/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$115.00 ➝ $123.00
7/31/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
7/31/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $15.00
7/16/2025
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$58.00 ➝ $70.00
7/15/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$129.00 ➝ $142.00
7/11/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$105.00 ➝ $121.00
7/9/2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$13.00 ➝ $15.00
(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$4.79B1.01$1.86 per share7.37$18.39 per share0.74
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
$166.02M6.06N/AN/A$1.90 per share18.32
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$4.52 per shareN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$441.54M8.84$1.62 per share70.53$9.33 per share12.27
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$317M-$0.78N/A14.241.41-5.58%2.33%1.12%N/A
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$84.60M-$3.10N/AN/AN/A-49.89%-199.06%-25.71%N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$175.85M-$4.62N/AN/AN/AN/A-73.74%-56.67%N/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$35.46M$1.9359.3380.07N/A13.49%28.02%8.64%10/27/2025 (Estimated)

Latest ESTA, BLCO, SLNO, and TMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
-$0.54-$0.57-$0.03-$0.57$50.80 million$51.30 million
8/6/2025Q2 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.53-$0.09+$0.44-$0.09$3.91 million$32.66 million
7/30/2025Q2 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.07+$0.01-$0.18$1.25 billion$1.28 billion
7/30/2025Q2 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.48$0.92+$0.44$0.92$146.64 million$157.37 million
5/8/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29$0.70+$0.41$0.70$123.39 million$143.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76
1.55
0.98
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
5.72
3.36
2.05
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.21
19.64
19.64
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.61
9.86
9.17

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
72.91%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.76%
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
11.09%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,500353.99 million351.12 millionOptionable
Establishment Labs Holdings Inc. stock logo
ESTA
Establishment Labs
1,01828.92 million25.71 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3053.15 million47.17 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21034.09 million31.70 millionOptionable

Recent News About These Companies

TransMedics Group (NASDAQ:TMDX) Upgraded at Wall Street Zen
TransMedics Group (NASDAQ:TMDX) Price Target Raised to $123.00
TransMedics Group, Inc. (TMDX): A Bull Case Theory
TransMedics Group, Inc. (TMDX): A Bull Case Theory
TransMedics Group (NASDAQ:TMDX) Shares Gap Up After Earnings Beat

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$13.67 -0.13 (-0.93%)
Closing price 03:59 PM Eastern
Extended Trading
$13.66 -0.01 (-0.09%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Establishment Labs stock logo

Establishment Labs NASDAQ:ESTA

$34.80 -1.16 (-3.23%)
Closing price 04:00 PM Eastern
Extended Trading
$35.70 +0.90 (+2.60%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$82.35 +3.64 (+4.62%)
Closing price 04:00 PM Eastern
Extended Trading
$82.91 +0.56 (+0.68%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$114.50 -1.55 (-1.34%)
Closing price 04:00 PM Eastern
Extended Trading
$122.05 +7.55 (+6.59%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.